FINANCES: What resources were available to support the national program in the past?

OUTCOME: How many people received the treatment and prevention services that they need?

IMPACT: What is the trend among people who continue to fall ill or die? (actual and hypothetical in the absence of program)

Historical investments by funding source (2012-2023)

Global Fund investments: 2017-2019 Allocation period

Tuberculosis disbursements: \$14.9m TB/HIV disbursements: \$162m


2020-2022 Allocation period

Tuberculosis disbursements: \$18.2m TB/HIV disbursements: \$302m

Cross-cutting RSSH disbursements: \$44.9m


In 2021-2023, 42% of NSP need was funded.


TB financing¹



Investments by funding source and intervention (2024-2026)²


Total amount in budget: \$74m






Global Fund Results (2023)


HIV+ TB patients on ART: People with TB treated: People with drug-resistant TB 258k 11.9k on treatment: 1.23k




Bacteriologically confirmed pulmonary TB cases tested for rifampicin resistance




TB treatment outcomes






TB deaths (excluding HIV+)



23% reduction from 2012 to 2022




New TB cases (all forms)

Change in TB cases:

35% increase from 2012 to 2022

97% increase from 2000 to 2022



Detailed notes are available on the separate Explanatory Notes page

 $(https://www.theglobalfund.org/media/7871/other_countryresultsprofileexplanatory_notes_en.pdf)$

Source: Data submitted by the country as part of their Funding Request for 2020-22 allocation period; GF detailed budget data. These data sources contain a mix of historical figures and projections

²Source: Data submitted by the country as part of their Funding Request for 2023-25 allocation period; GF detailed budget data. These data sources contain a mix of historical figures and projections.